Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSA | P10619 | 3/20 | 0.49 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | DCAF1 | Q9Y4B6 | 1/20 | 0.43 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | CYP26A1 | O43174 | 4/20 | 0.42 |
| ▸ | FNTA | P49354 | 1/20 | 0.42 |
| ▸ | FNTB | P49356 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31549516 | 1.00 | CTSL (0.50) | CTSLCTSAS1PR3CTSSCTSK | |
| SCHEMBL26985458 | 1.00 | CTSL (0.50) | CTSLCTSAS1PR3CTSSCTSK | |
| SCHEMBL742765 | 1.00 | CTSL (0.50) | CTSLCTSAS1PR3CTSSCTSK | |
| SCHEMBL30879991 | 0.89 | DCAF1 (0.53) | CTSLCTSAS1PR3CTSSCTSK | |
| SCHEMBL4958137 | 0.89 | CTSL (0.49) | CTSLS1PR3CTSSCTSK | |
| SCHEMBL4597970 | 0.88 | CTSL (0.50) | CTSLS1PR3CTSSCTSKDCAF1 | |
| SCHEMBL29840672 | 0.88 | CTSL (0.50) | CTSLS1PR3CTSSCTSKDCAF1 | |
| SCHEMBL16690741 | 0.88 | CTSL (0.50) | CTSLS1PR3CTSSCTSKDCAF1 | |
| SCHEMBL5575604 | 0.88 | CTSL (0.50) | CTSLS1PR3CTSSCTSKDCAF1 | |
| SCHEMBL6778313 | 0.87 | CYP26A1 (0.42) | CTSLCTSSCTSKCYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138168-B1 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-20 | — | — | US | disclosed |
| EP-1987035-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093515-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN LA-ROCHE AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| US-20070191406-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191406-A1 | Heterocyclic antiviral compounds | CCR5, CX3CR1, CXCR1 | CTSL 2302/4885CTSA 2993/4885S1PR3 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.